ETFELA

ETFELA
Clinical data
Other names	N-Ethyl-N-(2,2,2-trifluoroethyl)lysergamide; LA-CH2CF3
Drug class	Serotonin receptor modulator
Identifiers
	IUPAC name (6aR,9R)-N-Ethyl-7-methyl-N-(2,2,2-trifluoroethyl)-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide;
CAS Number	3024529-99-2 ;
PubChem CID	163187757;
CompTox Dashboard (EPA)	DTXSID201337080 ;
Chemical and physical data
Formula	C20H22F3N3O
Molar mass	377.411 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(C(=O)[C@H]1CN(C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC(F)(F)F;
	InChI InChI=1S/C20H22F3N3O/c1-3-26(11-20(21,22)23)19(27)13-7-15-14-5-4-6-16-18(14)12(9-24-16)8-17(15)25(2)10-13/h4-7,9,13,17,24H,3,8,10-11H2,1-2H3/t13-,17-/m1/s1; Key:VAHPXTJQSWECIC-CXAGYDPISA-N;

ETFELA, also known as N-ethyl-N-(2,2,2-trifluoroethyl)lysergamide, is an analogue of lysergic acid diethylamide (LSD) first synthesized by Jason C. Parrish as part of the research team led by David E. Nichols. In studies in vitro, it was found to be slightly more potent than LSD itself.^[1]^[2]

Quick facts Clinical data, Other names ...

Chemistry